Andere Sprachen Viracta Therapeutics, Inc.

Aktien

A2QQRS

US92765F1084

VIRX

Verzögert Nasdaq Andere Börsenplätze 15:34:21 26.06.2024			% 5 Tage	% 1. Jan.
0,589 ^USD	+3,15 %		+3,51 %	+3,33 %

30.05.	Day One Biopharmaceuticals verkauft Priority Review Voucher für $108 Millionen	MT
24.05.	VIRACTA THERAPEUTICS, INC. : Oppenheimer behält die Bewertung Kaufen bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals Sale of its Priority Review Voucher	13.06.
XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher	12.06.
Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million	30.05.
Viracta Therapeutics Announces New Employment Inducement Grants	17.05.
Viracta Therapeutics Appoints Michael Faerm CFO	14.05.
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer	14.05.
Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer	14.05.
Sunesis: Q1 Earnings Snapshot	09.05.
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09.05.
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference	07.05.
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma	16.04.
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma	15.04.
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	15.04.
Viracta Therapeutics : HST 2024 – Presentation	15.04.
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01.04.
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01.04.
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	21.03.
Viracta Therapeutics, Inc. Announces Executive Changes	20.03.
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	20.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Viracta Therapeutics, Inc.

Aktien

A2QQRS

US92765F1084

VIRX

Andere Sprachen

Filter